Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy

$7.2M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Fred Hutchinson Cancer Center
Country	United States
Start Date	Feb 01, 2024
End Date	Jan 31, 2029
Duration	1,826 days
Number of Grantees	2
Roles	Principal Investigator; Co-Investigator
Data Source	NIH (US)
Grant ID	`10781320`

Grant Description

PROJECT SUMMARY/ABSTRACT Despite treatment advances over the past decade, metastatic prostate cancer (PC) remains a fatal disease. As such, there is an acute need for additional treatment options. The development of therapeutics that specifically target cell surface antigens represent an attractive approach. PSMA is a cell surface glycoprotein that is highly

expressed on PC and because PSMA is relatively restricted to prostatic tissues, it represents an ideal theranostic target (i.e. useful for both ‘therapy’ and ‘diagnostics’). 177Lu-PSMA-617, a PSMA-directed radioligand, was recently approved by the FDA. While this is clearly a welcome treatment option, the median PFS has been

reported to be